Skip to content

Dr. Molly Li

273
Dr. Molly Li
李兆澄
Share
qualifications
MBBS (HK) MRCP (UK) FHKCP FHKAM (medical oncology)
rank
Assistant Professor (Clinical) – Department of Clinical Oncology
orcid
0000-0002-6460-5514
email
molly@clo.cuhk.edu.hk

Specific Research / Sites of Interest


  • Lung Cancer

  • Targeted Therapy

  • Immunotherapy

  • Resistance mechanism to EGFR TKI

  • Tumour immune microenvironment & immunotherapy resistance

  • Development and validation of predictive biomarker in lung cancer

  • Circulating tumour DNA in lung cancer

Short Biography

Dr Molly Li received his medical degree (MBBS) from the University of Hong Kong in 2014 with distinction in medicine and psychiatry. He obtained specialist qualification in Medical Oncology in 2021. Dr Li had previously worked in Queen Elizabeth Hospital before joining the Chinese University of Hong Kong as Assistant Professor in 2022. His research interest is in immunotherapy and targeted therapy in lung cancer.

Dr Li is currently the principal investigator or co-investigator of more than 15 lung cancer clinical trials. He is also the principal investigator of a number of translational studies (resistance mechanism and tumour immune microenvironment of EGFR-mutation positive lung cancer after osimertinib failure; Intratumoral heterogeneity of ALK-mutated lung cancer) and preclinical studies testing novel drug combinations in cell lines and patient derived xenograft models. Dr Li published a first authored article in JAMA Oncology prospectively validating the accuracy and demonstrating the clinical utility of EGFR testing from pleural effusion cell-free DNA. Based on the study findings, this test has been adopted as standard of care Prince of Wales Hospital and has benefited patients. (KWC Lee, MSC Li*…TSK Mok. JAMA Oncology 2022). He was awarded Direct Grant from the Chinese University of Hong Kong (2022), Young Investigator Research Grant from Hong Kong College of Physicians (2022), ESMO Asia Travel Grant from Hong Kong Cancer Therapy Society (2022) and Young Investigator Grant from the International Association for the Study of Lung Cancer (2022). Dr Li has served as a reviewer for multiple journals including Translational Lung Cancer Research, Cancer Treatment Reviews, etc. He has been an invited speaker in multiple local and regional events and conferences. Dr Li is also selected as a participant of the ASCO Leadership Development Programme Asia Pacific 2023-2024.

Most Representative Publications

1. A. Rohatgi, J. C. H. Yang, D. W. Kim, M. S. C. Li, J. Park, A. Setp, J Zhang, N Peled (2023) VELOCITY-Lung: A phase 2 study evaluating safety and efficacy of sacituzumab govitecan (SG) plus zimberelimab (zim) plus etrumadenant (etruma) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) progressing on or after platinum (PT)- based chemotherapy and checkpoint inhibitors (CPI). In American Association of Cancer Research Annual Meeting 2023
2. Li MSC, Mok KKS, Mok TSK (2023) Developments in Targeted Therapy & Immunotherapy -- how non-small cell lung cancer management will change in the next decade: a narrative review Annals of Translational Medicine. https://doi:10.21037/atm-22-4444 (IF 3.6)
3. Lok Seng Chan, Johnson Liu, Molly S C Li, Lili Li, Qian Tao, Tony S K Mok (2023) Selenite as a Dual Apoptotic and Ferroptotic Agent Synergizes with EGFR and KRAS inhibitors with epigenetic interference. Clinical Epigenetics. 2023 Mar 2;15(1):36. https://doi.org/10.1186/s13148-023-01454-4 (IF 7.3)
4. Joyce W. Y. Chan, Ivan C. H. Siu, Aliss T. C. Chang, Molly S. C. Li, Rainbow W.H. Lau, Tony S. K. Mok, Calvin S. H. Ng (2023) Transbronchial Techniques for Lung Cancer Treatment: Where Are We Now? In Cancers 2023, 15(4), 1068; https://doi.org/10.3390/cancers15041068 (IF 6.9)
5. K. W. C. Lee, M. S. C. Li*, W. Gai, Y. M. Lau, A. K. C. Chan, O. S. H. Chan, C. K. Lee, R. M. W. Yeung, S. Y. H. Fung, W. F. Cheung, V. W. Chan, L. Leung, K. N. P. Kam, T. S. K. Mok. EGFR Mutation Testing in Pleural and Pericardial Effusion Cell-free DNA from Lung Cancer: A Prospective Validation Study. (*co-first authorship). JAMA Oncology. 2022 Dec 29. https://doi:10.1001/jamaoncol.2022.6109 (IF: 31.8)
6. J. K. M. Ng, C. Chow, R. C. K. Chan, K. P. Chan, J. J. X. Li, M. S. C. Li, K. F. To. EGFR Testing in cell block cytology material is reliable with increased detection for effusion fluid. In Lung Cancer. 2022 Dec; 174:97-103. https://doi:10.1016/j.lungcan.2022.10.013. (IF: 5.7)
7. M. S. C. Li, K. Mok, T. Mok (2022). A Detouring Experience Not Recommended: Lessons Learnt from PD00299804. In Cancer Research 2022 Oct 17;82(20):3662-3664. https://doi.org/10.1158/0008-5472. (IF: 13.3)
8. Loong, H. H., Li, M. S. C., Tang, G. C. H., & Lau, Y. M. (2020). Have We Revealed the Achilles’ Heel of Brigatinib? Implications on Clinical Practice. In Journal of Thoracic Oncology 2020 Jul; 15(7): 1100-1102. https://doi:10.1016/j.jtho.2020.03.026 (IF: 15.6)